Teleflex (NYSE:TFX) said today that it closed its $1.1 billion acquisition of NeoTract and its UroLift prostate treatment. The deal called for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said. The UroLift system for benign prostate hyperplasia uses tiny devices that are […]
Urology
KKR puts another $35m into Signostics parent company EchoNous
Private equity giant KKR (NYSE:KKR) put another $235 million into EchoNous, the parent company of Signostics, for the second time in as many years. The cash is earmarked for commercializing the Uscan ultrasound device, developing a vein-location device and an unnamed artificial intelligence-driven ultrasound project to market, Seattle-based EchoNous said. KKR put $35 million into the company […]
Procept BioRobotics treats first patients in Water II test of surgical robot
Procept BioRobotics announced today that the first patients were treated in its Water II Study, a clinical trial testing the safety and efficacy of Aquablation delivery by its surgical robotic AquaBeam System to treat benign prostatic hyperplasia. The trials test the use of the system in prostates 80 to150 mL and will enroll 100 patients […]
Cardinal Health inks distro deal with Avadim Tech
Life science company Avadim Technologies said yesterday it inked a deal withCardinal Health (NYSE:CAH) to distribute Avadim’s Theraworx topical bionome therapies designed to prevent catheter-associated urinary tract infections and complications. The companies said that the Theraworx topical solution will compliment Cardinal Health’s Dover urological portfolio. “We are honored to partner with one of the most influential […]
Cook Medical urology biz launches Mauna Kea’s Cellvizio
UPDATE: Corrected to reflect that the launch was global, and not limited to the US. Cook Medical said today its urology business has launched Mauna Kea‘s (ENT:MKEA) Cellvizio confocal laser endomicroscopy system, with a deal to distribute the device globally. The Cellvizio device is designed for use in a variety of surgical procedures, providing real […]
Teleflex to pay $1.1B for NeoTract
Teleflex (NYSE:TFX) said today that it agreed to put up $1.1 billion to acquire NeoTract and its UroLift prostate treatment. The deal calls for an up-front cash payment of $725 million, plus another $375 million in milestone payments pegged to sales numbers through 2020, Wayne, Pa.-based Teleflex said. The deal is expected to close within 30 days. The […]
Profound Medical raises $8m for urology, women’s health devices
Profound Medical (TSX:PRN) said today that it inked an $8 million “bought” deal” financing with a pair of underwriters that it plans to use for its Tulsa-Pro and Sonalleve ablation devices. The funding, by Echelon Wealth Partners and CIBC Capital Markets, involved 10 million units at 80¢ (C$1 ) apiece, consisting of a stock share and […]
Women’s urinary incontinence device startup Elidah looks to raise $2m
Women’s health device start-up Elidah is looking to raise $2 million to support its Elitone stress urinary incontinence-treating device, according to a Connecticut Post report. The Elitone device, developed by the Newtown, Conn.-based company, is designed to be worn during the day and provides 20 minutes of electrical stimulation to strengthen pelvic muscles and aid […]
Cogentix Medical buys UK-based Genesis Medical
Cogentix Medical (NSDQ:CGNT) said today it acquired London-based Genesis Medical for an undisclosed amount. Genesis Medical produces, sells and markets urology products in the U.K. and operated as the exclusive regional distributor for Cogentix’s PrimeSight endoscopy systems. Cogentix said it purchased all tangible assets of Genesis, and will pay up to an additional $671,560 (GBP £515,000) […]
Boston Scientific joins OAB device dev Amphora Medical’s $36m Series B
Amphora Medical said today it closed a $35.5 million Series B financing round, led by major medtech player Boston Scientific (NYSE:BSX), with funds slated to support a US pivotal trial of its Selective Bladder Denervation System for treating women with overactive bladder. Amphora’s Selective Bladder Denervation System is a minimally-invasive, cystopic device which uses targeted ablation […]
NxThera adds $6m for Rezūm prostate device
NxThera said this week that it added another $6 million to its coffers in an ongoing round of debt financing. The Maple Grove, Minn.-based company is offering convertible promissory notes and Series C preferred stock warrants in the round, according to the filing, with the first sale logged Jan. 13. NxThera said it’s looking to raise […]